All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc. Īmgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen.
In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.įor more information, visit and follow us on Twitter, LinkedIn, Instagram, TikTok and YouTube. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.Īmgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.Īmgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.
The dividend will be paid on Septemto all stockholders of record as of the close of business on Aug.Ībout Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023.
0 kommentar(er)
